DS Research

Dermatology Specialists Research

  • Home
  • Who We Are
    • About
    • Meet Nina M. Scott
    • Meet Our Doctors
    • Meet Our Staff
  • Facilities
    • Kentucky Facility
    • Indiana Facility
    • Travel Accommodations
  • Research Studies
    • Enrolling Studies
  • Sponsor/CRO
  • News
  • Contact

The Emergence of TYK2 Inhibitors in Psoriasis Treatment: A Synopsis

May 23, 2023 by admin

Key Takeaways:

  1. Psoriasis remains undertreated in the US due to factors such as concerns about side effects, monitoring requirements, and the use of injectable treatments.
  2. TYK2 inhibitors, like orally administered deucravacitinib, represent a promising new treatment option for psoriasis.
  3. Numerous hurdles, including treatment costs, specialist availability, insurance coverage, and safety concerns need addressing for effective psoriasis care.

Understanding the Under-treatment of Psoriasis in the United States

Psoriasis, a prevalent skin disorder marked by the rapid build-up of skin cells, remains an undertreated condition in the United States. This is largely due to multiple factors, such as patient and physician apprehension about side effects, requirements for lab monitoring, and anxiety concerning injectable therapies. In a recent presentation at Dermatology Week 2023, Jeffrey M. Cohen, MD, highlighted the potential of TYK2 inhibitors as an exciting new treatment approach for this chronic disease.

The Emergence of TYK2 Inhibitors: A New Hope for Psoriasis Patients

TYK2 inhibitors, with deucravacitinib leading the way, are an emerging class of oral medications that could offer a promising alternative for psoriasis patients, particularly those hesitant about injections.

Deucravacitinib: The Forefront of TYK2 Inhibitors

Approved by the FDA, deucravacitinib is taken orally at a dose of 6 mg per day and functions by obstructing the signaling pathway from two key proteins, IL-12 and IL-23, which are responsible for activating Th17 cells – the primary instigators in psoriasis development. Dr. Cohen suggested that deucravacitinib could serve as a first-line therapy or as a treatment for patients who haven’t responded satisfactorily to other therapeutic options, such as injectable biologics. In certain cases, there could also be an opportunity to combine deucravacitinib with other treatments to control acute flares. However, he emphasized that more research is needed in this regard to establish the safety and effectiveness of such combination therapy.

Addressing Barriers to Effective Psoriasis Care

However, the path to widespread TYK2 inhibitor use isn’t without hurdles. Issues such as treatment costs, dermatologist availability, insurance coverage, and safety concerns pose significant barriers to psoriasis care. Dr. Cohen strongly advocated for the need to address these barriers through strategies that promote patient satisfaction and enhance treatment adherence.

The Importance of Shared Decision-Making in Psoriasis Management

Moreover, shared decision-making emerged as a fundamental component of psoriasis management, according to Dr. Cohen. This can be achieved through the use of decision aids, clearly explaining to patients their treatment options, and designing treatment plans centered around patient preferences.

Strategies to Enhance Patient Adherence to Psoriasis Treatment

To boost adherence to therapy, he recommended regular follow-ups after starting treatment, use of telemedicine, patient education, and linking medication use to specific daily actions.

The adoption of TYK2 inhibitors for psoriasis treatment may pave the way to improving patient outcomes and satisfaction. As we continue to monitor the developments in this field, the importance of overcoming care barriers and promoting shared decision-making cannot be overstated.

Learn more about Dr. Cohen’s presentation on The Dermatologist, Linked Here.

Dermatology Research

Contact Us

DS Research – Kentucky Location
3810 Springhurst Blvd.
Suite 130
Louisville, KY 40241
O: 502.585.9059
F: 502.585.9708

DS Research – Indiana Location
1005 E. Lewis & Clark Pkwy
Clarksville, IN 47129
O: 502.373.2849
F: 502.373.2872

Interested About Coming To Us? Our doctors are ready to see you now.

  • This field is for validation purposes and should be left unchanged.

dsrtrials

Are you tired of wrinkles? DS Research is now enro Are you tired of wrinkles? DS Research is now enrolling for a new study with a topical cream for Crow’s Feet. Call us today to find out if you qualify for this new cosmetic study!!! 
.
.
.
.
#cosmetics #wrinkles #crowsfeet #botox #dermatology #dsresearch #skin #kentucky #indiana #clinicaltrials
Call us today if you are interested in one of our Call us today if you are interested in one of our paid clinical trials for dermatology conditions!🌟
.
.
.
.
.
#research #dermatology #louisville #kentucky #clarksville #indiana #dermatologyresearch #clinicaltrials #skin #paidtrials
Are you struggling with #eczema? Call us today to Are you struggling with #eczema? Call us today to find out how we can help!
New Enrolling Studies⭐️⭐️⭐️ Give us a New Enrolling Studies⭐️⭐️⭐️ Give us a call today for more information on how we can help you achieve clear skin💚
.
.
.
.
.
.
#dsresearch #dermatology #kentucky #indiana #skin #eczema #psoriasis #alopecia #allergies #research #clinicaltrials
Load More... Follow on Instagram
This error message is only visible to WordPress admins
Error: Access Token is not valid or has expired. Feed will not update.

Copyright © 2023 DS Research :: Dermatology Specialists Research

  • Facebook
  • Instagram
  • LinkedIn
  • Pinterest
  • Twitter